SML2263

Ladostigil tartrate

≥98% (HPLC)

• Synonym(e): (3R)-(N-Propargylaminoindan-5-yl)-ethyl methyl carbamate tartrate (2:1), TV-3326, TV3326
• Empirische Formel (Hill-System): C₁₆H₂₀N₂O₂ · 0.5C₄H₆O₆
• CAS-Nummer: 209394-46-7
• Molekulargewicht: 347.39
• MDL-Nummer: MFCD22741393
• UNSPSC-Code: 12352200

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: powder
• Lagerbedingungen: desiccated
• Farbe: white to beige
• Löslichkeit: H₂O: 2 mg/mL, clear
• Lagertemp.: 2-8°C
• SMILES String: N([C@@H]3CCc4c3cc(cc4)OC(=O)N(CC)C)CC#C.N([C@@H]1CCc2c1cc(cc2)OC(=O)N(CC)C)CC#C.O[C@H]([C@@H](O)C(=O)O)C(=O)O
• InChI: 1S/2C16H20N2O2.C4H6O6/c2*1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2;5-1(3(7)8)2(6)4(9)10/h2*1,6,8,11,15,17H,5,7,9-10H2,2-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t2*15-;1-,2-/m111/s1
• InChIKey: PRLVBVAJMQZMJN-OGOSNNLPSA-N

Beschreibung

Biochem./physiol. Wirkung

Ladostigil, a carbamate is also a butyryl cholinesterase (BuChE) inhibitor.[1] It possesses anti-inflammatory property and effectively reduces the levels of tumor necrosis factor α (TNF-α) in lipopolysaccharide (LPS)-activated macrophages.[1] It provides protection to cardiomyocytes.[2] Ladostigil has neuroprotective functionality and has the potential to treat mild cognitive impairment (MCI) and spatial memory deficits development.[3] It also exhibits protective effects during oxidative and nitrative stress.[3]

Multifunctional drug designed to treat Alzhemier′s disease by combining in a single molecule the neuroprotective/neurorestorative effects of the (MAO)-B inhibitor rasagiline with the cholinesterase (ChE) inhibitory activity of rivastigmine.

Multifunctional drug designed to treat Alzhemier′s disease by combining in a single molecule the neuroprotective/neurorestorative effects of the (MAO)-B inhibitor rasagiline with the cholinesterase (ChE) inhibitory activity of rivastigmine.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable